All In Biotech

Drug Trial Radar · NCT02042196

Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women

Biological Mechanisms of Vascular Dysfunction With Age and Estrogen Deficiency

Last checked: Nov 20, 2026Latest source record: Jul 11, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Planned (sponsor's estimate)

Start

Dec 2013

Primary completion

May 2, 2016

Study completion May 2, 2016

Sponsor

Lead sponsor
University of Colorado, DenverAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
First posted
Jan 22, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

As women get older and go through menopause, levels of the female reproductive hormone estradiol decrease to low levels. Also with aging, the functioning of the arteries declines. Over time this vascular dysfunction can lead to health problems such as high blood pressure and heart disease. This study is being done to help determine what causes arteries to become unhealthy in postmenopausal women, who have low levels of the female reproductive hormone estradiol. In this study we will test whether low levels of tetrahydrobiopterin (BH4), a natural substance in the body that can cause the arteries to expand, explains why arteries become unhealthy in women with low levels of estradiol. To answer this question, we will study how vascular function changes with a medication that causes a short-term increase in BH4 levels when estradiol is lowered with a medication, compared to when estradiol is normal. We will also determine whether the administration of the antioxidant vitamin C, along with the medication to increase BH4 levels, will normalize vascular health in perimenopausal and postmenopausal women, and in women who have their estradiol levels lowered.

Conditions

  • Menopause
  • Aging

Interventions

  • KUVANDrug

    KUVAN will be given orally at 10mg/kg dose per body weight. KUVAN will be dissolved in 4-8oz water and consumed within 15 minutes.

  • PlaceboDrug

    Placebo pills designed to match the dissolvable KUVAN pills

  • CetrotideDrug

    Cetrotide (0.25mg/d) will be taken daily for 10 days via abdominal subcutaneous injection.

  • ClimaraDrug

    0.075mg/d transdermal patch will be placed on skin.

  • Placebo transdermal patchDrug

    Inactive transdermal patch

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in brachial artery flow-mediated dilationTime frame: 4-5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Colorado Denver

    Aurora, Colorado

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.